1. Home
  2. IRMD vs ABUS Comparison

IRMD vs ABUS Comparison

Compare IRMD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iRadimed Corporation

IRMD

iRadimed Corporation

HOLD

Current Price

$96.26

Market Cap

910.4M

Sector

Health Care

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.75

Market Cap

848.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRMD
ABUS
Founded
1992
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
910.4M
848.1M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
IRMD
ABUS
Price
$96.26
$4.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$72.00
$5.00
AVG Volume (30 Days)
74.4K
1.1M
Earning Date
11-03-2025
11-13-2025
Dividend Yield
0.71%
N/A
EPS Growth
13.00
N/A
EPS
1.65
N/A
Revenue
$80,511,268.00
$14,606,000.00
Revenue This Year
$15.17
$125.30
Revenue Next Year
$10.15
N/A
P/E Ratio
$58.33
N/A
Revenue Growth
12.91
116.64
52 Week Low
$47.48
$2.71
52 Week High
$98.44
$5.10

Technical Indicators

Market Signals
Indicator
IRMD
ABUS
Relative Strength Index (RSI) 75.36 60.87
Support Level $94.94 $4.43
Resistance Level $98.44 $4.63
Average True Range (ATR) 2.15 0.19
MACD 0.08 0.04
Stochastic Oscillator 80.50 89.66

Price Performance

Historical Comparison
IRMD
ABUS

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: